Experts And Viewpoints, October 02, 2006 An Expert Interview With Dr. Cal Cohen Recent approvals of new HIV drugs and a rich ... comparison of commercial phenotypic tests, and more.

Ireland based pharmaceutical company Gilead Sciences has said it will grant licences to six generic manufacturers to produce low cost lenacapavir, which has shown unprecedented efficacy at preventing ...

Feeling the chill and want to imbibe in some delicious apple cider this fall? The Food and Drug Administration has a warning ...

frequently within the context of commercial sex work (Shankle 2006). Needle injection practices may also increase risk for HIV through unsafe injection of recreational drugs or substances to alter ...

The global pharmaceutical industry will generate more than $1.2 trillion in sales in 2025, according to Statista. A large portion of that figure is from the oncology segment, which is expected ...

An organization that provides syringe services is facing eviction from its headquarters on Grant Street in Framingham.

and we have to address some of these things to reduce new HIV infections. There is also the role of the key population I earlier mentioned – the commercial sex workers, use of injected drugs ...

Researchers at Liverpool University found the drug could profitably be produced for as little as $40 per patient per year, if it were being purchased in large volumes. The terms of the new deal ...

The Biden administration on Monday proposed making over-the-counter contraception available at no cost and with fewer ...

Rwanda is making its third bid of investing in pharma, seeking to put pension funds in an industry with great potential but ...

QUVIVIQ™ is a potential best-in-class treatment in the high-growth, dual orexin antagonist class of medicines treating sleep ...

Magdalena aiming to submit Investigational New Drug (IND) application in early 2025 to the FDA for a next-generation psychoactive prescription drug candidate for potential mental health indications ...